<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547454</url>
  </required_header>
  <id_info>
    <org_study_id>ML22069</org_study_id>
    <nct_id>NCT02547454</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)</brief_title>
  <official_title>Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This observational trial will examine the efficacy and safety of Mircera for renal anemia in
      participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by
      treating physician and followed for approximately 36 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2008</start_date>
  <completion_date type="Actual">November 30, 2014</completion_date>
  <primary_completion_date type="Actual">November 30, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 1-3</measure>
    <time_frame>At Months 1-3</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 4-6</measure>
    <time_frame>At Months 4-6</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 7-9</measure>
    <time_frame>At Months 7-9</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 10-12</measure>
    <time_frame>At Months 10-12</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 13-15</measure>
    <time_frame>At Months 13-15</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 16-18</measure>
    <time_frame>At Months 16-18</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 19-21</measure>
    <time_frame>At Months 19-21</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) After 21 Months up to 36 Months</measure>
    <time_frame>After 21 Months up to 36 Months</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (100 to 130 g/L) at Baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 1-3</measure>
    <time_frame>At Months 1-3</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 4-6</measure>
    <time_frame>At Months 4-6</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 7-9</measure>
    <time_frame>At Months 7-9</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 10-12</measure>
    <time_frame>At Months 10-12</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 13-15</measure>
    <time_frame>At Months 13-15</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 16-18</measure>
    <time_frame>At Months 16-18</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 19-21</measure>
    <time_frame>At Months 19-21</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) After 21 Months up to 36 Months</measure>
    <time_frame>After 21 Months up to 36 Months</time_frame>
    <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time in Which Hb Value Was Maintained Within Target Range of 110-120 g/L</measure>
    <time_frame>Up to 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time in Which Hb Value Was Maintained Within Target Range of 100-130 g/L</measure>
    <time_frame>Up to 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Dose of Methoxy Polyethylene Glycol-Epoetin Beta</measure>
    <time_frame>Baseline</time_frame>
    <description>Average dose of methoxy polyethylene glycol-epoetin beta administered at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Dose of Methoxy Polyethylene Glycol-Epoetin Beta</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and After 21 Months up to 36 Months</time_frame>
    <description>Median monthly dose of methoxy polyethylene glycol-epoetin beta administered in the study up to 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose Adaptations</measure>
    <time_frame>Up to 36 Months</time_frame>
    <description>Total number of changes (increase or decrease) in daily methoxy polyethylene glycol-epoetin beta doses. The reasons for dose-adaptations included: inflammation or infection; kidney function decline; over-response; iron deficiency; insufficient response; adverse effect; start of maintenance dose; kidney function improvement; re-introduction of treatment; and others (other reasons than specified).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Dose 0</measure>
    <time_frame>Up to 36 Months</time_frame>
    <description>Percentage of participants who did not use methoxy polyethylene glycol-epoetin beta (Dose 0) at atleast one visit during study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Iron Replacement</measure>
    <time_frame>Up to 36 Months</time_frame>
    <description>Iron replacement was given to the participants either in oral iron replacement or intravenous replacement or both.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">393</enrollment>
  <condition>Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>CKD participants treated with Mircera</arm_group_label>
    <description>Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxy polyethylene glycol-epoetin beta</intervention_name>
    <arm_group_label>CKD participants treated with Mircera</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with CKD who do not require dialysis and are appropriate for treatment with
        Mircera according to European Best Practice Guidelines (EBPG) and Kidney Disease Outcomes
        Quality Initiative (K/DOQI) guidelines.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants aged &gt; 18 years with CKD

          -  Participants who are eligible for Mircera treatment according to current guidelines
             and summary of product characteristics (SmPC)

        Exclusion Criteria:

          -  Non-renal anemia

          -  Pregnancy and breast-feeding

          -  Uncontrolled hypertension

          -  Known hypersensitivity to methoxy polyethylene glycol-epoetin beta

          -  Administration of any other study drug within 30 days prior to study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Celje; Dept For Kidney Disease &amp; Dialysis</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splosna Bolnisnica Izola; Oddelek Za Nefrologijo</name>
      <address>
        <city>Izola</city>
        <zip>6310</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Ljubljana; Clinical Dep. For Nephrology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nefroloska Ambulanta</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maribor; Clinical Dept For Internal Medicine</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splosna Bolnisnica Murska Sobota; Oddelek Za Nefrologijo</name>
      <address>
        <city>Murska Sobota</city>
        <zip>9000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdravstveni Zavod Medicinski Center Šinigoj Nova Gorica</name>
      <address>
        <city>Nova Gorica</city>
        <zip>5000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Novo Mesto; Dialysis Dept</name>
      <address>
        <city>Novo Mesto</city>
        <zip>8000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr.Joze Potre; Dialysis Dept</name>
      <address>
        <city>Ptuj</city>
        <zip>2250</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splosna Bolnisnica Franc Derganc; Oddelek Za Nefrologijo</name>
      <address>
        <city>Sempeter Pri Novi Gorici</city>
        <zip>5390</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Slovenj Gradec; Hemodialysis Dept</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Splosna Bolnisnica Trbovlje; Oddelek Za Nefrologijo</name>
      <address>
        <city>Trbovlje</city>
        <zip>1420</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>October 21, 2015</results_first_submitted>
  <results_first_submitted_qc>October 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2015</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Participants with chronic kidney disease (CKD), who did not require dialysis, received methoxy polyethylene glycol-epoetin beta (Mircera) either intravenously (IV) or subcutaneously (SC), as per routine clinical practice, and were followed for approximately 36 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Due to hemodialysis</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to transplantation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to no further need to treat</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No data</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="393"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 1-3</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 1-3</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 1-3</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 4-6</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 4-6</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 4-6</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 7-9</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 7-9</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 7-9</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 10-12</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 10-12</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 10-12</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 13-15</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 13-15</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 13-15</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 16-18</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 16-18</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 16-18</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 19-21</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 19-21</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 19-21</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) After 21 Months up to 36 Months</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>After 21 Months up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) After 21 Months up to 36 Months</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (100 to 130 g/L) at Baseline</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Baseline</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (100 to 130 g/L) at Baseline</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 1-3</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 1-3</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 1-3</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 4-6</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 4-6</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 4-6</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 7-9</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 7-9</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 7-9</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 10-12</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 10-12</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 10-12</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 13-15</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 13-15</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 13-15</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 16-18</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 16-18</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 16-18</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 19-21</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>At Months 19-21</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 19-21</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) After 21 Months up to 36 Months</title>
        <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
        <time_frame>After 21 Months up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) After 21 Months up to 36 Months</title>
          <description>If a participant had more than 1 assessment during the specified time frame, the last observed Hb value was considered for calculation.</description>
          <population>Analysis population included all enrolled participants who had at least one Hb assessment at the specified time frame.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time in Which Hb Value Was Maintained Within Target Range of 110-120 g/L</title>
        <time_frame>Up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time in Which Hb Value Was Maintained Within Target Range of 110-120 g/L</title>
          <population>Analysis population included all enrolled participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time (full range) to obtain Hb value within the target range was not possible to analyze due to fluctuation within and outside of range.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time in Which Hb Value Was Maintained Within Target Range of 100-130 g/L</title>
        <time_frame>Up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time in Which Hb Value Was Maintained Within Target Range of 100-130 g/L</title>
          <population>Analysis population included all enrolled participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time (full range) to obtain Hb value within the target range was not analyzed due to fluctuation within and outside of range.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Dose of Methoxy Polyethylene Glycol-Epoetin Beta</title>
        <description>Average dose of methoxy polyethylene glycol-epoetin beta administered at Baseline</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dose of Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Average dose of methoxy polyethylene glycol-epoetin beta administered at Baseline</description>
          <population>Analysis population included all enrolled participants.</population>
          <units>microgram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Dose of Methoxy Polyethylene Glycol-Epoetin Beta</title>
        <description>Median monthly dose of methoxy polyethylene glycol-epoetin beta administered in the study up to 36 months.</description>
        <time_frame>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and After 21 Months up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants. Here, n signifies participants with available data at specified time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Dose of Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Median monthly dose of methoxy polyethylene glycol-epoetin beta administered in the study up to 36 months.</description>
          <population>Analysis population included all enrolled participants. Here, n signifies participants with available data at specified time-point.</population>
          <units>microgram</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=393)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="50" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="50" upper_limit="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="30" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="30" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="25" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15 (n=175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="0" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 21 Months up to 36 Months (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Dose Adaptations</title>
        <description>Total number of changes (increase or decrease) in daily methoxy polyethylene glycol-epoetin beta doses. The reasons for dose-adaptations included: inflammation or infection; kidney function decline; over-response; iron deficiency; insufficient response; adverse effect; start of maintenance dose; kidney function improvement; re-introduction of treatment; and others (other reasons than specified).</description>
        <time_frame>Up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Adaptations</title>
          <description>Total number of changes (increase or decrease) in daily methoxy polyethylene glycol-epoetin beta doses. The reasons for dose-adaptations included: inflammation or infection; kidney function decline; over-response; iron deficiency; insufficient response; adverse effect; start of maintenance dose; kidney function improvement; re-introduction of treatment; and others (other reasons than specified).</description>
          <population>Analysis population included all enrolled participants.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total dose adaptations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammation or infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney function decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iron deficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of maintenance phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney function improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-introduction of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Dose 0</title>
        <description>Percentage of participants who did not use methoxy polyethylene glycol-epoetin beta (Dose 0) at atleast one visit during study period.</description>
        <time_frame>Up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Dose 0</title>
          <description>Percentage of participants who did not use methoxy polyethylene glycol-epoetin beta (Dose 0) at atleast one visit during study period.</description>
          <population>Analysis population included all enrolled participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Iron Replacement</title>
        <description>Iron replacement was given to the participants either in oral iron replacement or intravenous replacement or both.</description>
        <time_frame>Up to 36 Months</time_frame>
        <population>Analysis population included all enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
            <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Iron Replacement</title>
          <description>Iron replacement was given to the participants either in oral iron replacement or intravenous replacement or both.</description>
          <population>Analysis population included all enrolled participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral Iron Replacement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intravenous Iron Replacment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral and Intravenous Iron Replacment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Iron Replacment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 36 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methoxy Polyethylene Glycol-Epoetin Beta</title>
          <description>Participants with CKD, who did not require dialysis, received methoxy polyethylene glycol-epoetin beta either IV or SC, as per routine clinical practice, and were followed for approximately 36 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Epileptic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

